Lexaria Bioscience (Lexaria Bioscience) Cash-to-Debt : 32.39 (As of Feb. 2024)

View and export this data going back to 2006. Start your Free Trial

What is Lexaria Bioscience Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Lexaria Bioscience's cash to debt ratio for the quarter that ended in Feb. 2024 was 32.39.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Lexaria Bioscience could pay off its debt using the cash in hand for the quarter that ended in Feb. 2024.

The historical rank and industry rank for Lexaria Bioscience's Cash-to-Debt or its related term are showing as below:

LEXX' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.72 Med: 120.62 Max: No Debt
Current: 32.39

During the past 13 years, Lexaria Bioscience's highest Cash to Debt Ratio was No Debt. The lowest was 0.72. And the median was 120.62.

LEXX's Cash-to-Debt is ranked better than
69.31% of 1538 companies
in the Biotechnology industry
Industry Median: 6.485 vs LEXX: 32.39

Lexaria Bioscience Cash-to-Debt Historical Data

The historical data trend for Lexaria Bioscience's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Lexaria Bioscience Cash-to-Debt Chart

Lexaria Bioscience Annual Data

Trend

Oct13

Aug15

Aug16

Aug17

Aug18

Aug19

Aug20

Aug21

Aug22

Aug23

Cash-to-Debt

Get a 7-Day Free Trial

No Debt

8.42

121.16

123.22

9.01

Lexaria Bioscience Quarterly Data
	May19	Aug19	Nov19	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23	Nov23	Feb24
Cash-to-Debt	Get a 7-Day Free Trial															122.07	19.62	9.01	12.99	32.39

Competitive Comparison of Lexaria Bioscience's Cash-to-Debt

For the Biotechnology subindustry, Lexaria Bioscience's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Lexaria Bioscience's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lexaria Bioscience's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Lexaria Bioscience's Cash-to-Debt falls into.

Lexaria Bioscience Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Lexaria Bioscience's Cash to Debt Ratio for the fiscal year that ended in Aug. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	1.478	/	(0.028	+	0.136)
	=	9.01

Lexaria Bioscience's Cash to Debt Ratio for the quarter that ended in Feb. 2024 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	4.793	/	(0.026	+	0.122)
	=	32.39

Lexaria Bioscience (NAS:LEXX) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Lexaria Bioscience Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Lexaria Bioscience's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Lexaria Bioscience (Lexaria Bioscience) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lexaria Bioscience Corp (NAS:LEXX) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

740 McCurdy Road, Suite 100, Kelowna, BC, CAN, V1X 2P7

Website

https://www.lexariabioscience.com

Lexaria Bioscience Corp's patented drug delivery technology, DehydraTECH improves the way active pharmaceutical ingredients enter the bloodstream by promoting more effective oral delivery. DehydraTECH has the ability to increase bio-absorption with cannabinoids and nicotine by 5-10x and, in some instances with cannabinoids by as much as 27x compared to standard industry formulations, reduce the time of onset from 1-2 hours to minutes, and mask unwanted tastes. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. The Company has four reportable segments: Intellectual Property Licensing, B2B Production, Research and Development and Corporate. It earns maximum revenue from Intellectual Property Licensing.

Executives

Catherine C. Turkel	director	19900 MACARTHUR BLVD., SUITE 550, IRVINE CA 92612
Gregory Downey	officer: Chief Financial Officer	100 - 740 MCCURDY ROAD, KELOWNA A1 V1X 2P7
Christopher Bunka	director, 10 percent owner, officer: CEO	1924 BIRKDALE AVE, KELOWNA A1 V1P1R7
Vanessa Carle	officer: Secretary	100 - 740 MCCURDY ROAD, KELOWNA A1 V1X 2P7
Reese Albert L Jr	director
Brian W. Quigley	director	100 740 MCCURDY ROAD, KELOWNA A1 23230
William Edward Mckechnie	director	305 MARGARET AVENUE, KITCHENER A6 N2H 6S4
Allan Horst Spissinger	officer: CFO	8131 198A STREET, LANGLEY A1 V2Y 1Y6
John Martin Docherty	director, 10 percent owner	23 MIKELEN DRIVE, PORT PERRY A6 L9L 1V1
Baljinder Bhullar	director, officer: CFO	604 - 700 WEST PENDER, VANCOUVER A1 V6C 1G8
Nicholas W Baxter	director	220 SPRINGFIELD ROAD, ABERDEEN, ABERDEENSHIRE, SCOTLAND X0 AB15 6AU
Dustin Arthur Elford	director	888 - 609 WEST HASTINGS STREET, VANCOUVER A1 V6B 4W4
Thomas James Ihrke	officer: Sr. VP, Business Development	38 KRIER LANE, MOUNT PLEASANT SC 29464
David Demartini	director, 10 percent owner	11714 SPRIGGS WAY, HOUSTON TX 77024
Leonard Macmillan	director, officer: Vice President - Corp Develop	SUITE 302, 125A - 1030 DENMAN STREET, VANCOUVER A1 V6G 2M6